RegulatoryApr 6, 2026, 11:54 AM
ImmunityBio Responds to FDA Warning Letter Regarding Prescription Drug Promotion
AI Summary
ImmunityBio submitted a comprehensive response to a Warning Letter issued by the FDA concerning the promotion of its prescription drugs. The company outlined immediate and planned corrective actions, indicating a regulatory challenge and potential impact on its marketing practices.
Key Highlights
- ImmunityBio received a Warning Letter from the FDA's Office of Prescription Drug Promotion on March 13, 2026.
- The company submitted a response to the FDA on April 6, 2026, detailing corrective actions.
- The press release regarding the response is furnished as Exhibit 99.1 to the 8-K filing.